Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis.

PubWeight™: 1.53‹?› | Rank: Top 4%

🔗 View Article (PMID 25010665)

Published in Ann Surg on May 01, 2015

Authors

Parissa Tabrizian1, Ghalib Jibara, Brian Shrager, Myron Schwartz, Sasan Roayaie

Author Affiliations

1: *Mount Sinai Medical Center, New York, NY †Department of Urology, the Brookdale's University Hospital and Medical Center, Brooklyn, NY ‡Department of Surgery, Morristown Medical Center, Morristown, NJ; and §Liver Cancer Program, North Shore-LIJ Health Systems, Lenox Hill Hospital, New York, NY.

Articles by these authors

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93

The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33

Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05

Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18

Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42

Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39

A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32

Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29

Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol (2008) 2.22

Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18

Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98

Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol (2007) 1.95

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77

Hepatic resection for primary hepatolithiasis: a single-center Western experience. J Am Coll Surg (2012) 1.70

IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66

Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol (2013) 1.65

Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol (2002) 1.52

Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology (2009) 1.48

The beneficial impact of temporary porto-caval shunt in orthotopic liver transplantation: a single center analysis. Transpl Int (2010) 1.48

Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis (2011) 1.46

De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45

Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl (2004) 1.44

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44

Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg (2004) 1.36

Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on "Surgical Misinterpretation" of the BCLC Staging System. Ann Surg (2015) 1.17

Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant (2004) 1.17

Feasibility and preliminary accuracy of high-resolution imaging of the liver and pancreas using FNA compatible microendoscopy (with video). Gastrointest Endosc (2012) 1.09

Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest (2012) 1.09

Intravascular epithelioid hemangioendothelioma of the inferior vena cava: case report of an unusual and unpredictable vascular tumor. Cardiovasc Pathol (2008) 1.09

Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery (2007) 1.07

Hilar cholangiocarcinoma involving the portal vein bifurcation: long-term results after resection. J Hepatobiliary Pancreat Surg (2002) 1.03

Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl (2009) 1.02

Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center's experience. Am J Surg (2008) 1.02

Second hepatic resection for recurrent hepatocellular cancer: a Western experience. J Hepatol (2010) 1.00

Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center. Ann Surg (2014) 0.99

How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? J Hepatol (2005) 0.97

Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist (2005) 0.96

Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One (2012) 0.95

Liver transplantation for neuroendocrine tumors. J Gastrointest Surg (2004) 0.93

Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. Target Oncol (2013) 0.91

Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis (2011) 0.91

Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant (2004) 0.91

Recurrence of hepatocellular carcinoma after liver transplantation: is immunosuppression a factor? Liver Transpl (2005) 0.90

The incidence and significance of late acute cellular rejection (>1000 days) after liver transplantation. Clin Transplant (2004) 0.88

Epstein-Barr virus-associated smooth muscle tumors in children following solid organ transplantation: a review. Pediatr Transplant (2015) 0.88

Multifocal hepatocellular carcinoma and precancerous lesions in a patient with autoimmune hepatitis-related cirrhosis. Semin Liver Dis (2008) 0.88

Resection of hepatocellular carcinoma without cirrhosis. Ann Surg (2012) 0.87

Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg (2003) 0.87

Trefoil factor-3 expression in human colon cancer liver metastasis. Clin Exp Metastasis (2008) 0.87

Retracted Liver functional reserve estimation: state of the art and relevance to local treatments. Oncology (2010) 0.86

Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). Abdom Imaging (2011) 0.86

Does anatomic versus nonanatomic resection affect recurrence and survival in patients undergoing surgery for colorectal liver metastasis? Ann Surg Oncol (2008) 0.86

Outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the elderly. Surg Oncol (2013) 0.86

Giant hemangioma of the adrenal. Isr Med Assoc J (2004) 0.85

Establishing an international training program for surgical residents. J Surg Educ (2007) 0.85

Actual 10-year survival following hepatectomy for hepatocellular carcinoma. HPB (Oxford) (2013) 0.84

Cancer history and other personal factors affect quality of life in patients with hepatitis C. Health Qual Life Outcomes (2005) 0.84

Primary hepatic signet ring cell neuroendocrine tumor: a case report with literature review. Semin Liver Dis (2010) 0.84

Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors. J Clin Oncol (2013) 0.84

Carcinoma ex microcystic adenoma of the pancreas: a report of a novel form of malignancy in serous neoplasms. Am J Surg Pathol (2012) 0.83

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. J Gastrointest Surg (2014) 0.83

Marked Differences in acute cellular rejection rates between living-donor and deceased-donor liver transplant recipients. Transplantation (2005) 0.83

Liver functional reserve estimation: state of the art and relevance for local treatments: the Western perspective. J Hepatobiliary Pancreat Sci (2009) 0.83